Artículos de revistas sobre el tema "Genetically engineered drugs"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Genetically engineered drugs".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Jones-Grizzle, Amy J. y J. Lyle Bootman. "Pharmacoeconomics of Genetically Engineered Drugs". PharmacoEconomics 1, n.º 1 (enero de 1992): 45–53. http://dx.doi.org/10.2165/00019053-199201010-00009.
Texto completoKishore, Kamal y Pawan Krishan. "Pharmacology of recombinant or genetically engineered drugs". Journal of Young Pharmacists 1, n.º 2 (2009): 141. http://dx.doi.org/10.4103/0975-1483.55747.
Texto completoKhobeysh, M. M. y E. V. Sokolovskiy. "Genetically engineered biologics to treat psoriasis. Experience with ustekinumab in an adolescent with severe psoriasis". Meditsinskiy sovet = Medical Council, n.º 1 (12 de marzo de 2023): 123–29. http://dx.doi.org/10.21518/ms2023-003.
Texto completoМатюнова, Алла, Alla Matyunova, Людмила Брегель y Lyudmila Bregel. "MODERN JUVENILE IDIOPATHIC ARTHRITIS THERAPY OF WITH THE USE OF BIOLOGICAL MEDICATIONS IN A REGIONAL CHILDREN”S 3 LEVEL HOSPITAL - RESULTS AND PROBLEMS". Acta biomedica scientifica 2, n.º 5 (18 de enero de 2018): 102–6. http://dx.doi.org/10.12737/article_5a3a0e4744a0a8.88140750.
Texto completoHuang, Ya Qiong, Kenneth L. White, De Shun Shi, Xu Jian Chen, Jia Zhou Li, Shi Yuan Zeng, Shi Hua Zhao y Gui Wen Ruan. "Development and Prospect of Genetically Engineered Pharmaceutics". Advanced Materials Research 746 (agosto de 2013): 588–92. http://dx.doi.org/10.4028/www.scientific.net/amr.746.588.
Texto completoZyryanov, S. K. y O. I. Butranova. "Genetically engineered drugs for treatment of bronchial asthma: recent achievements". Russian Pulmonology 28, n.º 5 (24 de diciembre de 2018): 584–601. http://dx.doi.org/10.18093/0869-0189-2018-28-5-584-601.
Texto completoLeonova, K. "Selected problems in the use of genetic engineering biological therapy in patients with rheumatoid arthritis". Clinical Medicine and Pharmacology 6, n.º 4 (2 de febrero de 2021): 36–39. http://dx.doi.org/10.12737/2409-3750-2021-6-4-36-39.
Texto completoAvdeev, Sergey N., Alexandr V. Emelyanov, Oksana M. Kurbacheva, Irina M. Marusenko, Pavel I. Novikov, Olga A. Rizakhanova y Larisa V. Shul’zhenko. "A new delivery device for benralizumab (autoinjector, pen-injector device) in the clinical practice of treating severe eosinophilic asthma: Conclusion of the Expert Council". PULMONOLOGIYA 31, n.º 6 (16 de diciembre de 2021): 776–81. http://dx.doi.org/10.18093/0869-0189-2021-31-6-776-781.
Texto completoCho, Kyungjoo, Simon Weonsang Ro, Sang Hyun Seo, Youjin Jeon, Hyuk Moon, Do Young Kim y Seung Up Kim. "Genetically Engineered Mouse Models for Liver Cancer". Cancers 12, n.º 1 (19 de diciembre de 2019): 14. http://dx.doi.org/10.3390/cancers12010014.
Texto completoSamigullina, R. R., V. I. Mazurov y E. A. Trofimov. "Characteristics of complex therapy of immuno-inflammatory rheumatic diseases in COVID-19 pandemic conditions". Russian Medical Inquiry 5, n.º 5 (2021): 260–67. http://dx.doi.org/10.32364/2587-6821-2021-5-5-260-267.
Texto completoZaytseva, Svetlana V., Anna U. Tomilova, Olga V. Zaytseva, Olga B. Voronina, Olga A. Murtazaeva, Valeriy A. Mukhortykh y Irina N. Tsymbal. "Genetically Engineered Biologic Drugs in Management of Children with Bronchial Asthma". Pediatric pharmacology 18, n.º 6 (16 de noviembre de 2021): 460–68. http://dx.doi.org/10.15690/pf.v18i6.2325.
Texto completoDorogoykina, K. D. Dorogoykina, D. S. Sedov Sedov, K. A. Gamayunova Gamayunova y A. P. Rebrov Rebrov. "Kidney condition in patients with spondyloarthritis receiving genetically engineered biologic drugs". Nephrology 2_2020 (29 de junio de 2020): 21–25. http://dx.doi.org/10.18565/nephrology.2020.2.21-25.
Texto completoZhuravleva, L. "Problems of diagnosis and treatment of systemic lupus erythematosus in a young girl". Clinical Medicine and Pharmacology 8, n.º 4 (1 de febrero de 2023): 30–32. http://dx.doi.org/10.12737/2409-3750-2023-8-4-30-32.
Texto completoNovoderezhkina, Evgeniya A. y Sergey K. Zyryanov. "Estimating the indirect costs associated with psoriasis". Kazan medical journal 103, n.º 5 (3 de octubre de 2022): 824–31. http://dx.doi.org/10.17816/kmj2022-824.
Texto completoSvechnikova, E. V. y S. E. Zhufina. "A modern view on the treatment of psoriatic disease. Experience in using genetically engineered biological therapy in patients with extensive moderate to severe psoriasis". Meditsinskiy sovet = Medical Council, n.º 6 (27 de abril de 2022): 216–25. http://dx.doi.org/10.21518/2079-701x-2022-16-6-216-225.
Texto completoDidenko, V. V., G. A. Kalashnik, Ju Ju Karpenko y E. N. Harlamova. "Description of the Clinical Case of Adalimumab and Secukinumab Therapy of a Patient with Psoriatic Arthritis". Russian Archives of Internal Medicine 11, n.º 3 (31 de mayo de 2021): 225–28. http://dx.doi.org/10.20514/2226-6704-2021-11-3-225-228.
Texto completoKruglova, L. S., A. A. Hotko y M. Yu Pomazanova. "Issues of switching therapy when effect of biological genetically engineered drugs escapes". Medical alphabet, n.º 24 (20 de diciembre de 2020): 48–52. http://dx.doi.org/10.33667/2078-5631-2020-24-48-52.
Texto completoSvechnikova, E. V., Z. B. Marshani, K. A. Fomin y E. Yu Evdokimov. "Genetically engineered biological drugs in psoriasis treatment in the COVID-19 pandemic". Klinicheskaya dermatologiya i venerologiya 20, n.º 5 (2021): 95. http://dx.doi.org/10.17116/klinderma20212005195.
Texto completoPrimrose, S. B. "The application of genetically engineered micro-organisms in the production of drugs". Journal of Applied Bacteriology 61, n.º 2 (agosto de 1986): 99–116. http://dx.doi.org/10.1111/j.1365-2672.1986.tb04263.x.
Texto completoMeshcherina, N. S., L. A. Knyazeva, I. I. Goryainov y L. I. Knyazeva. "Vasoprotective Effects of Genetically Engineered Biologic Drugs in Patients with Rheumatoid Arthritis". Sovremennye tehnologii v medicine 7, n.º 3 (septiembre de 2015): 130–37. http://dx.doi.org/10.17691/stm2015.7.3.18.
Texto completoKagramanova, Anna V., Oleg V. Knyazev, Oleg V. Knyazev, Oleg V. Knyazev, Dmitrii S. Kulakov, Dmitrii S. Kulakov, Dmitrii S. Kulakov et al. "Interdisciplinary approach is a key of efficient treatment in patients with immunoinflammatory diseases. Case report". Consilium Medicum 23, n.º 5 (2021): 440–43. http://dx.doi.org/10.26442/20751753.2021.5.200821.
Texto completoKruglova, L. S., E. A. Shatokhina, A. S. Polonskaya y A. Yu Syryseva. "Choice of frst drug of genetically engineered therapy: Benefts of guselcumab". Medical alphabet, n.º 8 (18 de mayo de 2022): 48–55. http://dx.doi.org/10.33667/2078-5631-2022-8-48-55.
Texto completoTarasova, D. D., L. N. Shilova, M. V. Korolyova, E. G. Korenskaya y A. V. Feoktistova. "Ulcerative colitis in combination with ankylosing spondylitis: clinical case". Experimental and Clinical Gastroenterology 183, n.º 11 (14 de noviembre de 2020): 147–50. http://dx.doi.org/10.31146/1682-8658-ecg-183-11-147-150.
Texto completoVarticovski, L., M. G. Hollingshead, M. R. Anver, A. I. Robles, J. E. Green, K. W. Hunter, G. Merlino et al. "Preclinical testing using tumors from genetically engineered mouse mammary models". Journal of Clinical Oncology 24, n.º 18_suppl (20 de junio de 2006): 10067. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.10067.
Texto completoShilova, L. N. y S. S. Spitsina. "Possibilities of personalized approach to genetically engineered biological therapy of rheumatoid arthritis". Medical alphabet, n.º 16 (19 de agosto de 2021): 35–40. http://dx.doi.org/10.33667/2078-5631-2021-16-35-40.
Texto completoMohd Janib, Siti Najila, Radu O. Minea, Steve D. Swenson, ShuangLong Liu, Martha K. Pastuszka, Frank S. Markland, Peter S. Conti, ZiBo Li y J. Andrew Mackay. "The Design of Elastin-Like Polypeptides (ELPs) as a Nanoparticulate-Based Therapeutic and Diagnostic Imaging Agent". Advanced Materials Research 1024 (agosto de 2014): 287–91. http://dx.doi.org/10.4028/www.scientific.net/amr.1024.287.
Texto completoKalmykov, R. S., E. M. Safonenkov y L. P. Zharkova. "THE USE OF GENETICALLY ENGINEERED BIOLOGICAL DRUGS FOR THERAPY WITH SARS-COV-2". Вестник Смоленской государственной медицинской академии 21, n.º 2 (2022): 49–53. http://dx.doi.org/10.37903/vsgma.2022.2.7.
Texto completoKito, Hiroyuki, Fumiaki Suzuki, Shunji Nagahara, Yasuhide Nakayama, Yoko Tsutsui, Nobumasa Tsutsui, Nobuyuki Nakajima y Takehisa Matsuda. "A Total Delivery System of Genetically Engineered Drugs or Cells for Diseased Vessels". ASAIO Journal 40, n.º 3 (julio de 1994): M260—M266. http://dx.doi.org/10.1097/00002480-199407000-00005.
Texto completoBalabanova, Rimma Mikhailovna, V. N. Amirdzhanova y E. L. Nasonov. "USE OF GENETICALLY ENGINEERED BIOLOGICAL DRUGS FOR RHEUMATOID ARTHRITIS IN THE RUSSIAN FEDERATION". Rheumatology Science and Practice, n.º 6 (15 de diciembre de 2012): 10. http://dx.doi.org/10.14412/1995-4484-2012-1286.
Texto completoHwang, Insung. "Change in Regulation is Necessary for Genetically Engineered Mosquitoes". Michigan Journal of Environmental & Administrative Law, n.º 6.1 (2016): 285. http://dx.doi.org/10.36640/mjeal.6.1.change.
Texto completoMazhar, Sayyeda Farwa, Muhammad Afzal, Ahmad Almatroudi, Samman Munir, Usman Ali Ashfaq, Maria Rasool, Hammad Raza, Hafiz Muhammad Waqas Munir, Muhammad Shahid Riaz Rajoka y Mohsin Khurshid. "The Prospects for the Therapeutic Implications of Genetically Engineered Probiotics". Journal of Food Quality 2020 (7 de abril de 2020): 1–11. http://dx.doi.org/10.1155/2020/9676452.
Texto completoProtzer, U. y H. Abken. "Can Engineered “Designer” T Cells Outsmart Chronic Hepatitis B?" Hepatitis Research and Treatment 2010 (21 de septiembre de 2010): 1–9. http://dx.doi.org/10.1155/2010/901216.
Texto completoDoehmer, J., A. Seidel, F. Oesch y H. R. Glatt. "Genetically engineered V79 Chinese hamster cells metabolically activate the cytostatic drugs cyclophosphamide and ifosfamide." Environmental Health Perspectives 88 (agosto de 1990): 63–65. http://dx.doi.org/10.1289/ehp.908863.
Texto completoDmitrieva, A. A. y E. V. Dmitriev. "Risks of uveitis recurrence in juvenile idiopathic arthritis". Modern technologies in ophtalmology, n.º 6 (9 de noviembre de 2022): 71–75. http://dx.doi.org/10.25276/2312-4911-2022-6-71-75.
Texto completoChesi, Marta, Geoffrey M. Matthews, Victoria M. Garbitt, Stephen E. Palmer, Jake Shortt, Marcus Lefebure, A. Keith Stewart, Ricky W. Johnstone y P. Leif Bergsagel. "Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy". Blood 120, n.º 2 (12 de julio de 2012): 376–85. http://dx.doi.org/10.1182/blood-2012-02-412783.
Texto completoNekhaeva, Tatyana, A. Chernov, Yana Toropova, Mikhail Galagudza y Irina Baldueva. "VARIETY OF TUMOR MODELS FOR TESTING ANTITUM TREATMENT ACTIVITY OF SUBSTANCES IN MICE". Problems in oncology 66, n.º 4 (1 de abril de 2020): 353–63. http://dx.doi.org/10.37469/0507-3758-2020-66-4-353-363.
Texto completoBurashnikova, I. S. Burashnikova. "The rationale for re-administration of genetically engineered biological drugs in patients with COVID-19". Pharmateca 8_2021 (16 de agosto de 2021): 11–14. http://dx.doi.org/10.18565/pharmateca.2021.8.11-14.
Texto completoSatybaldyev, Azamat Makhmudovich. "Giant cell arteritis. Part III. New trends in its treatment (role of genetically engineered drugs)". Modern Rheumatology Journal, n.º 1 (15 de marzo de 2013): 30. http://dx.doi.org/10.14412/1996-7012-2013-2364.
Texto completoMeghani, Zahra. "Genetically Engineered Animals, Drugs, and Neoliberalism: The Need for a New Biotechnology Regulatory Policy Framework". Journal of Agricultural and Environmental Ethics 30, n.º 6 (21 de noviembre de 2017): 715–43. http://dx.doi.org/10.1007/s10806-017-9696-1.
Texto completoStolyarov, I. D., G. N. Bisaga, M. V. Votintseva, A. G. Ilves, I. G. Nikiforova, N. V. Nikolaeva, M. S. Rudas et al. "Some modern methods of diagnosis and pathogenetic therapy of multiple sclerosis". Neurology Bulletin XXXIV, n.º 1-2 (15 de abril de 2002): 65–72. http://dx.doi.org/10.17816/nb87566.
Texto completoAlekseeva, Ekaterina I., Dariya D. Van’kova, Margarita A. Soloshenko, Tatyana M. Dvoryakovskaya, Kseniya B. Isaeva, Rina V. Denisova, Anna V. Mamutova, Aleksandra M. Chomahidze, Nikolay A. Mayanskiy y Natalya E. Tkachenko. "Pneumococcal Vaccine in Patients with Systemic Juvenile Idiopathic Arthritis Receiving Biologic Therapy: International Practice Review". Current Pediatrics 18, n.º 2 (23 de junio de 2019): 101–8. http://dx.doi.org/10.15690/vsp.v18i2.2012.
Texto completoRosochkina, E. A., G. V. Lukina, E. N. Koltsova, K. A. Lytkina, E. I. Shmidt, A. I. Zagrebneva y E. V. Zhilyaev. "Comparative efficacy of genetically engineered biological drugs in real clinical practice according to the Moscow Unified Arthritis Registry (MUAR) data". Russian Medical Inquiry 5, n.º 2 (2021): 58–63. http://dx.doi.org/10.32364/2587-6821-2021-5-2-58-63.
Texto completoSevostyanov, V. K., P. S. Lototskaya, N. V. Babich, D. D. Rassoha, A. S. Novikov, S. L. Balashov y E. S. Zholobova. "ANALYSIS OF THE SURVIVAL OF GENETICALLY ENGINEERED BIOLOGICAL THERAPY IN JUVENILE IDIOPATHIC ARTHRITIS". Pediatria. Journal named after G.N. Speransky 101, n.º 4 (19 de agosto de 2022): 55–63. http://dx.doi.org/10.24110/0031-403x-2022-101-4-55-63.
Texto completoGalstyan, L. A., E. S. Zholobova, S. N. Chebysheva, A. V. Meleshkina, V. A. Seraya y O. Yu Loskutova. "Uveitis associated with juvenile idiopathic arthritis". Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) 64, n.º 2 (15 de mayo de 2019): 30–37. http://dx.doi.org/10.21508/1027-4065-2019-64-2-30-37.
Texto completoNascimento-Gonçalves, Elisabete, Bruno A. L. Mendes, Rita Silva-Reis, Ana I. Faustino-Rocha, Adelina Gama y Paula A. Oliveira. "Animal Models of Colorectal Cancer: From Spontaneous to Genetically Engineered Models and Their Applications". Veterinary Sciences 8, n.º 4 (5 de abril de 2021): 59. http://dx.doi.org/10.3390/vetsci8040059.
Texto completoSiegfried, Michael. "The Inner City in the 21st Century". Journal of Interdisciplinary Studies 8, n.º 1 (1996): 19–30. http://dx.doi.org/10.5840/jis199681/22.
Texto completoBurashnikova, I. S. Burashnikova. "The rationale for the combined use of genetically engineered biological drugs in patients with COVID-19". Pharmateca 8_2021 (16 de agosto de 2021): 15–19. http://dx.doi.org/10.18565/pharmateca.2021.8.15-19.
Texto completoSizova, Ol'ga Aleksandrovna, Nataliya Vladimirovna Efremova y Zoya Sergeevna Rumyantseva. "LUNG DAMAGE AS A COMPLICATION OF SYSTEMIC JUVENILE ARTHRITIS". Ulyanovsk Medico-biological Journal, n.º 4 (26 de diciembre de 2022): 38–48. http://dx.doi.org/10.34014/2227-1848-2022-4-38-48.
Texto completoMeshcheryakova, A. y A. Vorobyova. "CHRONIC DEMYELINIZING POLYNEUROPATHY: ETIOPATHOGENETIC, CLINICAL ASPECTS, MODERN DIRECTIONS OF MEDICAL THERAPY". National Association of Scientists 1, n.º 67 (15 de junio de 2021): 23–25. http://dx.doi.org/10.31618/nas.2413-5291.2021.1.67.423.
Texto completoSiddeswari T, Panneerselvam P, Vijayamma G, Nithya Kalyani K, Jeslin D y Suryasree Y. "Design and validation of the Gingkolide estimation using RP-HPLC analytical tool". International Research Journal of Pharmaceutical and Applied Sciences 11, n.º 1 (26 de febrero de 2021): 1–5. http://dx.doi.org/10.26452/irjpas.v11i1.1394.
Texto completo